Half-year report · Q2
8086.TEDINET S100UQIB
Period2024-04-01 → 2024-09-30
Filed2024-11-14
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 47
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥312.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net sales |
| Revenue | ¥586.8bn | 2023-04-01 → 2024-03-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥285.9bn | 2023-04-01 → 2023-09-30 | Cons. | Net sales |
| Operating income | ¥13.5bn | 2024-04-01 → 2024-09-30 | Cons. | Operating income |
| Operating income | ¥13.5bn | 2023-04-01 → 2023-09-30 | Cons. | Operating income |
| Ordinary income | ¥4.5bn | 2024-04-01 → 2024-09-30 | Cons. | Ordinary income |
| Ordinary income | ¥19.5bn | 2023-04-01 → 2024-03-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥14.7bn | 2023-04-01 → 2023-09-30 | Cons. | Ordinary income |
| Profit before tax | ¥4.1bn | 2024-04-01 → 2024-09-30 | Cons. | Income before income taxes |
| Profit before tax | ¥17.5bn | 2023-04-01 → 2023-09-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥129m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥11.1bn | 2023-04-01 → 2024-03-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥9.9bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥813m | 2024-04-01 → 2024-09-30 | Cons. | Profit loss |
| Net income | ¥10.4bn | 2023-04-01 → 2023-09-30 | Cons. | Profit loss |
| Total assets | ¥1.17T | at 2024-09-30 | Cons. | Assets |
| Total assets | ¥1.11T | at 2024-03-31 | Cons. | Assets |
| Total assets | ¥1.10T | at 2023-09-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥875.4bn | at 2024-09-30 | Cons. | Liabilities |
| Total liabilities | ¥840.0bn | at 2024-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥298.1bn | at 2024-09-30 | Cons. | Net assets |
| Net assets / equity | ¥269.8bn | at 2024-03-31 | Cons. | Net assets |
| Net assets / equity | ¥274.0bn | at 2023-09-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥92.6bn | at 2024-09-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥99.7bn | at 2024-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥85.0bn | at 2024-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥96.6bn | at 2024-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥83.8bn | at 2023-09-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥84.7bn | at 2023-03-31d | Cons. | Cash and cash equivalents |
| Operating cash flow | ¥15.0bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥72.9bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥18.7bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥54.8bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥87.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥35.5bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | ¥23.3bn | 2024-04-01 → 2024-09-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥22.1bn | 2023-04-01 → 2024-03-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥8.9bn | 2023-04-01 → 2023-09-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥0.79 | 2024-04-01 → 2024-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥68.12 | 2023-04-01 → 2024-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥60.89 | 2023-04-01 → 2023-09-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥0.7 | 2024-04-01 → 2024-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥60.35 | 2023-04-01 → 2024-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥53.95 | 2023-04-01 → 2023-09-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 22.1% | at 2024-09-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 21.0% | at 2024-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 21.6% | at 2023-09-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 54
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-04-01 → 2024-09-30 | ¥3.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-04-01 → 2024-09-30 | ¥383m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥2.6bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-04-01 → 2024-09-30 | −¥272m |
| Reconciling Itemsreconciling | revenue | 2024-04-01 → 2024-09-30 | −¥39.9bn |
| Reconciling Itemsreconciling | revenue intersegment | 2024-04-01 → 2024-09-30 | −¥39.9bn |
| Reconciling Itemsreconciling | segment profit | 2024-04-01 → 2024-09-30 | −¥14.9bn |
| jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥245.6bn |
| jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥242.1bn |
| jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥3.6bn |
| jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥24.5bn |
| jpcrp040300-q2r_E02688-000Medicine Relatedreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥68.4bn |
| jpcrp040300-q2r_E02688-000Medicine Relatedreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥38.0bn |
| jpcrp040300-q2r_E02688-000Medicine Relatedreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥30.4bn |
| jpcrp040300-q2r_E02688-000Medicine Relatedreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥3.2bn |
| jpcrp040300-q2r_E02688-000Pharma Packagingreportable segment | revenue | 2024-04-01 → 2024-09-30 | ¥34.9bn |
| jpcrp040300-q2r_E02688-000Pharma Packagingreportable segment | revenue external | 2024-04-01 → 2024-09-30 | ¥31.6bn |
| jpcrp040300-q2r_E02688-000Pharma Packagingreportable segment | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥3.3bn |
| jpcrp040300-q2r_E02688-000Pharma Packagingreportable segment | segment profit | 2024-04-01 → 2024-09-30 | ¥931m |
| —segment total | revenue | 2024-04-01 → 2024-09-30 | ¥348.9bn |
| —segment total | revenue external | 2024-04-01 → 2024-09-30 | ¥311.6bn |
| —segment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥37.3bn |
| —segment total | segment profit | 2024-04-01 → 2024-09-30 | ¥28.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-04-01 → 2024-09-30 | ¥351.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-04-01 → 2024-09-30 | ¥312.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2024-04-01 → 2024-09-30 | ¥39.9bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-04-01 → 2024-09-30 | ¥28.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2023-04-01 → 2023-09-30 | ¥2.5bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2023-04-01 → 2023-09-30 | ¥417m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥2.0bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2023-04-01 → 2023-09-30 | −¥109m |
| Reconciling Itemsreconciling | revenue | 2023-04-01 → 2023-09-30 | −¥36.1bn |
| Reconciling Itemsreconciling | revenue intersegment | 2023-04-01 → 2023-09-30 | −¥36.1bn |
| Reconciling Itemsreconciling | segment profit | 2023-04-01 → 2023-09-30 | −¥14.1bn |
| jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥223.6bn |
| jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥220.2bn |
| jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥3.3bn |
| jpcrp040300-q2r_E02688-000Medical Treatment Relatedreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥22.6bn |
| jpcrp040300-q2r_E02688-000Medicine Relatedreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥62.9bn |
| jpcrp040300-q2r_E02688-000Medicine Relatedreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥35.2bn |
| jpcrp040300-q2r_E02688-000Medicine Relatedreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥27.6bn |
| jpcrp040300-q2r_E02688-000Medicine Relatedreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥3.7bn |
| jpcrp040300-q2r_E02688-000Pharma Packagingreportable segment | revenue | 2023-04-01 → 2023-09-30 | ¥33.0bn |
| jpcrp040300-q2r_E02688-000Pharma Packagingreportable segment | revenue external | 2023-04-01 → 2023-09-30 | ¥30.0bn |
| jpcrp040300-q2r_E02688-000Pharma Packagingreportable segment | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥3.1bn |
| jpcrp040300-q2r_E02688-000Pharma Packagingreportable segment | segment profit | 2023-04-01 → 2023-09-30 | ¥1.4bn |
| —segment total | revenue | 2023-04-01 → 2023-09-30 | ¥319.5bn |
| —segment total | revenue external | 2023-04-01 → 2023-09-30 | ¥285.4bn |
| —segment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥34.0bn |
| —segment total | segment profit | 2023-04-01 → 2023-09-30 | ¥27.7bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2023-04-01 → 2023-09-30 | ¥321.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2023-04-01 → 2023-09-30 | ¥285.9bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2023-04-01 → 2023-09-30 | ¥36.1bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2023-04-01 → 2023-09-30 | ¥27.6bn |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 641
| Item | Context | Value | Unit |
|---|---|---|---|
| Payments for retirement of noncurrent assets inv cf | CurrentYTDDuration | -7000000 | JPY |
| Proceeds from governmental subsideies for investment in property and equipment inv cf | Prior1YTDDuration | 483000000 | JPY |
| Proceeds from governmental subsideies for investment in property and equipment inv cf | CurrentYTDDuration | － | JPY |
| Net decrease increase in short term loans receivable inv cf | Prior1YTDDuration | -3025000000 | JPY |
| Net decrease increase in short term loans receivable inv cf | CurrentYTDDuration | -2900000000 | JPY |
| Payments of loans receivable inv cf | Prior1YTDDuration | － | JPY |
| Payments of loans receivable inv cf | CurrentYTDDuration | -107000000 | JPY |
| Collection of loans receivable inv cf | Prior1YTDDuration | 48000000 | JPY |
| Collection of loans receivable inv cf | CurrentYTDDuration | 50000000 | JPY |
| Other payments inv cf | Prior1YTDDuration | -28000000 | JPY |
| Other payments inv cf | CurrentYTDDuration | － | JPY |
| Net cash provided by used in investment activities | Prior1YTDDuration | -35520000000 | JPY |
| Net cash provided by used in investment activities | CurrentYTDDuration | -54799000000 | JPY |
| Net increase decrease in short term loans payable fin cf | Prior1YTDDuration | 15447000000 | JPY |
| Net increase decrease in short term loans payable fin cf | CurrentYTDDuration | 19220000000 | JPY |
| Proceeds from long term loans payable fin cf | Prior1YTDDuration | 32210000000 | JPY |
| Proceeds from long term loans payable fin cf | CurrentYTDDuration | 53008000000 | JPY |
| Repayment of long term loans payable fin cf | Prior1YTDDuration | -34370000000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYTDDuration | -42543000000 | JPY |
| Redemption of bonds fin cf | Prior1YTDDuration | -1000000000 | JPY |
| Redemption of bonds fin cf | CurrentYTDDuration | -1000000000 | JPY |
| Proceeds from sales of treasury stock fin cf | Prior1YTDDuration | 0 | JPY |
| Proceeds from sales of treasury stock fin cf | CurrentYTDDuration | 0 | JPY |
| Purchase of treasury stock fin cf | Prior1YTDDuration | -0 | JPY |
| Purchase of treasury stock fin cf | CurrentYTDDuration | -0 | JPY |
| Proceeds from sale and leaseback fin cf | Prior1YTDDuration | 930000000 | JPY |
| Proceeds from sale and leaseback fin cf | CurrentYTDDuration | 546000000 | JPY |
| Repayments of finance lease obligations fin cf | Prior1YTDDuration | -1811000000 | JPY |
| Repayments of finance lease obligations fin cf | CurrentYTDDuration | -1798000000 | JPY |
| Cash dividends paid fin cf | Prior1YTDDuration | -1390000000 | JPY |
| Cash dividends paid fin cf | CurrentYTDDuration | -2448000000 | JPY |
| Dividends paid to non controlling interests fin cf | Prior1YTDDuration | -30000000 | JPY |
| Dividends paid to non controlling interests fin cf | CurrentYTDDuration | -252000000 | JPY |
| Repayments of installment payables fin cf | Prior1YTDDuration | -1058000000 | JPY |
| Repayments of installment payables fin cf | CurrentYTDDuration | -1389000000 | JPY |
| Net cash provided by used in financing activities | Prior1YTDDuration | 8926000000 | JPY |
| Net cash provided by used in financing activities | CurrentYTDDuration | 23342000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | Prior1YTDDuration | 6981000000 | JPY |
| Effect of exchange rate change on cash and cash equivalents | CurrentYTDDuration | 4775000000 | JPY |
| Net increase decrease in cash and cash equivalents | Prior1YTDDuration | -887000000 | JPY |
| Net increase decrease in cash and cash equivalents | CurrentYTDDuration | -11652000000 | JPY |
| Cash and cash equivalents | Prior2YearInstant | 84695000000 | JPY |
| Cash and cash equivalents | Prior1YearInstant | 96582000000 | JPY |
| Increase in cash and cash equivalents from newly consolidated subsidiary cce | Prior1YTDDuration | － | JPY |
| Increase in cash and cash equivalents from newly consolidated subsidiary cce | CurrentYTDDuration | 20000000 | JPY |
| Cash and cash equivalents | Prior1QuarterInstant | 83808000000 | JPY |
| Cash and cash equivalents | CurrentQuarterInstant | 84950000000 | JPY |
| Exporting notes receivable discounted | Prior1YearInstant | 20000000 | JPY |
| Exporting notes receivable discounted | CurrentQuarterInstant | 12000000 | JPY |
| Payroll and allowances sga | Prior1YTDDuration | 14208000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |